NCT02570373View on ClinicalTrials.gov

A Study to Characterize the Elimination of Guselkumab Glycoform Variants in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

September 25, 2015

Primary Completion Date

January 12, 2016

Study Completion Date

January 12, 2016

Conditions
Healthy
Interventions
DRUG

Guselkumab

Participant will receive a single intravenous (IV) infusion of guselkumab at a dose of 10 milligram per kilogram (mg/kg) over 60 minutes on Day 1.

Trial Locations (1)

Unknown

Tempe

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02570373 - A Study to Characterize the Elimination of Guselkumab Glycoform Variants in Healthy Participants | Biotech Hunter | Biotech Hunter